• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

    2/24/22 5:43:17 PM ET
    $PRTG
    Oil & Gas Production
    Energy
    Get the next $PRTG alert in real time by email

    WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the "third quarter").

    "During the third quarter and in recent weeks we've taken steps to accelerate our lead programs for PORT-2 and PORT-3, investigating options to expand our clinical sites beyond our current footprint and finding the means of accelerating patient enrollment," said Dr. Ian Walters, chief executive officer of Portage. "With our enhanced management team, efficient organization, and financial resources obtained in 2021, we are well positioned to execute our unique drug development strategy to deliver on important clinical milestones over the next two years."

    Business Update

    • Enhanced the management team with the appointments of Brian Wiley as Chief Business Officer, Joseph Ciavarella as Chief Accounting Officer; expanded the Board of Directors with the addition of Jim Mellon, Linda Kozick, and Mark Simon.
    • Enrollment continues in the Company's IMP-MEL randomized Phase 1/2 study of PORT-2 and its PRECIOUS Phase 1 study of PORT-3 in patients with NY-ESO-1 expressing tumors.
    • The Company plans to issue a Research & Development update in March 2022 which will include preliminary safety data on its PORT-2 and PORT-3 programs as well as other details from its clinical development plan.
    • Presented at high-profile investor conferences:
      • Management participated in January 2022 investor conferences including the LifeSci Advisors Corporate Access Event, H.C. Wainwright BioConnect Conference, and the B. Riley Securities' Oncology Investor Conference.
    • Hosted Key Opinion Webinar How iNKT Agonists Could Improve Immuno-Oncology Treatment with leading researchers from La Jolla Institute of Immunology and Imperial College London. Replay available here.

    Third Quarter FY 2022 Financial Results

    The Company generated a net loss and comprehensive loss of approximately $4.2 million in the three months ended December 31, 2021 ("Fiscal 2022 Quarter"), compared to a net loss and comprehensive loss of approximately $1.3 million in the three months ended December 31, 2020 ("Fiscal 2021 Quarter"), an increase in loss of $2.9 million year over year. Operating expenses, which include research and development and general and administrative expenses, were approximately $4.2 million in the Fiscal 2022 Quarter, compared to $0.9 million in the Fiscal 2021 Quarter, an increase of $3.3 million, which is discussed more fully below.

    The Company's other items of income and expense were substantially non-cash in nature and were approximately $0.1 million net income in the Fiscal 2022 Quarter, compared to approximately $0.5 million net loss in the Fiscal 2021 Quarter, a change in other items of income and expense of approximately $0.6 million, year over year. The primary reasons for the year over year difference in other items of income and expense was the change of $0.8 million in the fair value of the warrants issued with respect to the SalvaRx note settlement, which was partially offset by the year over year increase in the loss from an associate accounted for under the equity method of $0.1 million and the income on equity issued at a discount of $0.1 million in the Fiscal 2021 Quarter, representing the difference between the market price and the contractual exercise price, relating to the settlement of the SalvaRx notes and warrants.

    Research & development ("R&D") costs increased by approximately $1.5 million, from approximately $0.4 million during the Fiscal 2021 Quarter, to approximately $1.9 million during the Fiscal 2022 Quarter. The increase was primarily attributable to non-cash share-based compensation expense associated with grants made under the 2021 Equity Incentive Plan of $1.0 million and salaries and bonuses of $0.7 million to directors and senior management. Additionally, the Fiscal 2021 Quarter was impacted by a general slow down in expenditures resulting from the pandemic.

    General and administrative ("G&A") expenses increased by approximately $1.8 million, from approximately $0.4 million during the Fiscal 2021 Quarter, to approximately $2.2 million during the Fiscal 2022 Quarter. The principal reason for the increase in the Fiscal 2022 Quarter was the $1.1 million of non-cash share-based compensation expense associated with the Company's 2021 Equity Incentive Plan, of which $0.7 million is associated with Directors' compensation, and $0.4 million is associated with management compensation. No share-based compensation expense under the 2021 Equity Incentive Plan was incurred during the Fiscal 2021 Quarter. Additionally, the Company incurred an increase of $0.4 million in professional fees relating to initiatives associated with a corporate restructuring and public relations / business development. Finally, D&O insurance premiums increased $0.4 million in the current year period due to market rate increases in the cost of coverage.

    Additionally, the Company reflected a net income tax expense of approximately $0.1 million in the Fiscal 2022 Quarter, compared to a net income tax benefit of approximately $0.1 million in the Fiscal 2021 Quarter. The Fiscal 2022 Quarter reflects the change in the foreign currency exchange rate on deferred tax liability settleable in British pounds sterling and the Fiscal 2021 Quarter reflected recoverable research and development tax credits generated in the U.K.

    As of December 31, 2021, the Company had cash and cash equivalents of approximately $25.6 million and total current liabilities of approximately $0.6 million (inclusive of approximately $0.2 million warrant liability settleable on a non-cash basis). For the nine months ended December 31, 2021, the Company is reporting a net loss of approximately $10.3 million and cash used in operating activities of approximately $4.5 million. As of January 31, 2022, the Company had approximately $25.1 million of cash on hand to enable achieving important clinical milestones over the next two years.

    About Portage Biotech Inc.

    Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company's access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage's portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

    Forward-Looking Statements

    This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

    FOR MORE INFORMATION, PLEASE CONTACT:

    Investor Relations        

    Chuck Padala

    [email protected]

    Media Relations

    Gwen Schanker

    [email protected]

    -tables to follow-



    PORTAGE BIOTECH INC.

    Consolidated Statements of Operations and Comprehensive Income (Loss)

    (U.S. Dollars in thousands, except per share amounts)

      Three months ended

    December 31,
      Nine months ended

    December 31,
     
      2021  2020  2021  2020 
      In 000'$  In 000'$  In 000'$  In 000'$ 
    Expenses            
    Research and development $1,928  $414  $4,804  $1,658 
    General and administrative expenses  2,241   452   6,288   1,349 
    Loss from operations  (4,169)  (866)  (11,092)  (3,007)
    Change in fair value of warrant liability  342   (500)  726   (441)
    Share of (loss) income in associate accounted for using equity method  (261)  (121)  (363)  270 
    Income (loss) on equity issued at a discount  –   77   –   (1,256)
    Gain on sale of marketable equity securities  –   –   –   72 
    (Loss) on extinguishment of notes payable  –   –   –   (223)
    Foreign exchange transaction (loss)  –   (2)  –   (2)
    Interest (expense)  (1)  (3)   (42)  (172)
    Loss before provision for income taxes  (4,089)  (1,415)  (10,771)  (4,759)
    Income tax (expense) benefit  (117)  65   465   65 
    Net (loss)  (4,206)  (1,350)  (10,306)  (4,694)
    Other comprehensive income (loss)                
    Unrealized (loss) on investment  –   –   –   – 
    Total comprehensive (loss) for period $(4,206) $(1,350) $(10,306) $(4,694)
    Net (loss) income attributable to:                
    Owners of the Company $ (3,512) $(1,184) $(9,553) $(4,335)
    Non-controlling interest  (694)  (166)  (753)  (359)
      $(4,206) $(1,350) $(10,306) $(4,694)
    Comprehensive (loss) attributable to:                
    Owners of the Company $(3,512) $(1,184) $(9,553) $(4,335)
    Non-controlling interest  (694)  (166)  (753)  (359)
      $(4,206) $(1,350) $(10,306) $(4,694)
    (Loss) per share (Actual)                
    Basic and diluted $(0.26) $(0.10) $(0.74) $(0.37)
    Weighted average shares outstanding                
    Basic and diluted  13,344   12,031   12,966   11,619 

    PORTAGE BIOTECH INC.

    Consolidated Statements of Financial Position

    (U.S. Dollars in thousands)

    As of, December 31,

    2021
      March 31,

    2021
     
         (Audited) 
    Assets      
    Current assets      
    Cash and cash equivalents $25,603  $2,770 
    Prepaid expenses and other receivables  672   2,176 
       26,275   4,946 
    Long-term assets        
    Long-term portion of other receivables  –   22 
    Investment in associate  1,372   1,735 
    Investments in private companies  7,409   7,409 
    Goodwill  43,324   43,324 
    In-process research and development  117,388   117,388 
    Other assets  38   36 
    Total assets $195,806  $174,860 
             
    Liabilities and Equity        
    Current liabilities        
    Accounts payable and accrued liabilities $477  $1,938 
    Warrant liability  159   1,120 
    Unsecured notes payable  –   150 
       636   3,208 
    Non-current liabilities        
    Deferred tax liability  23,606   24,050 
       23,606   24,050 
    Total liabilities  24,242   27,258 
    Shareholders' Equity        
    Capital stock  158,294   130,649 
    Stock option reserve  14,225   7,977 
    Accumulated other comprehensive income  958   958 
    Accumulated deficit  (47,688)  (38,135)
    Total equity attributable to owners of the Company  125,789   101,449 
    Non-controlling interest  45,775   46,153 
    Total equity  171,564   147,602 
    Total liabilities and equity $195,806  $174,860 
    Commitments and Contingent Liabilities (Note 17)        


    Primary Logo

    Get the next $PRTG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTG

    DatePrice TargetRatingAnalyst
    7/18/2022$26.00Outperform
    Oppenheimer
    3/7/2022$32.00Buy
    HC Wainwright & Co.
    9/21/2021$30.00Outperform
    Oppenheimer
    9/2/2021$40.00Buy
    B. Riley Securities
    8/19/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

      DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano Mutti of the Department of Applied Clinical Sciences and Biotechnology at the University of L'Aquila, Italy, an internationally recognized expert in mesothelioma, will be presenting the data at the American Association for Cancer Research® (AACR) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on April 28, 2025. The new data in a murine mesothelioma model demonstrated single agent activity for PORT-7 that was s

      4/28/25 6:00:00 AM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

      DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. The new data demonstrate both single agent activity for PORT-7, and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant infiltra

      3/27/25 4:15:00 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

      DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the dose escalation stage for PORT-6, a highly selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial. Portage had previously paused this trial due to funding concerns; this resumption of the trial underscores the encouraging findings observed in earlier cohorts. After the completion of the PORT-6 arm of the ADPORT-601 study, Portage will evaluate the continuation of the study into its PORT-7

      3/12/25 8:00:34 AM ET
      $PRTG
      Oil & Gas Production
      Energy

    $PRTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Portage Biotech Inc.

      SC 13G/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

      11/14/24 4:26:22 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Amendment: SEC Form SC 13D/A filed by Portage Biotech Inc.

      SC 13D/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

      11/14/24 4:07:02 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • SEC Form SC 13G filed by Portage Biotech Inc.

      SC 13G - PORTAGE BIOTECH INC. (0001095435) (Subject)

      2/14/24 3:50:16 PM ET
      $PRTG
      Oil & Gas Production
      Energy

    $PRTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on Portage Biotech with a new price target

      Oppenheimer resumed coverage of Portage Biotech with a rating of Outperform and set a new price target of $26.00

      7/18/22 9:02:05 AM ET
      $PRTG
      Oil & Gas Production
      Energy
    • HC Wainwright & Co. initiated coverage on Portage Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Portage Biotech with a rating of Buy and set a new price target of $32.00

      3/7/22 6:24:57 AM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Oppenheimer initiated coverage on Portage Biotech with a new price target

      Oppenheimer initiated coverage of Portage Biotech with a rating of Outperform and set a new price target of $30.00

      9/21/21 4:56:17 AM ET
      $PRTG
      Oil & Gas Production
      Energy

    $PRTG
    Leadership Updates

    Live Leadership Updates

    See more
    • Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

      WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distin

      1/6/25 5:00:49 AM ET
      $PRTG
      Oil & Gas Production
      Energy

    $PRTG
    SEC Filings

    See more
    • SEC Form 424B3 filed by Portage Biotech Inc.

      424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)

      5/29/25 4:40:42 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • SEC Form 6-K filed by Portage Biotech Inc.

      6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)

      5/29/25 4:30:10 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • SEC Form EFFECT filed by Portage Biotech Inc.

      EFFECT - PORTAGE BIOTECH INC. (0001095435) (Filer)

      5/15/25 12:15:07 AM ET
      $PRTG
      Oil & Gas Production
      Energy

    $PRTG
    Financials

    Live finance-specific insights

    See more
    • Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

      WESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural killer T cell (iNKT agonist) platform and now fully owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired through Portage's iOx Therapeutics Ltd. (iOx) subsidiary from the founding equity holders in exchange for 1,070,000 ordinary shares of P

      7/20/22 9:00:00 AM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

      Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enters into committed share purchase agreement with Lincoln Park Capital to purchase ordinary shares of Portage for up to $30 Million; proceeds to potentially extend cash runway for current projects into 2024 Management to host a conference call and webcast Thursday, July 7 at 8:30am ET to discuss the adenosine programs and combined pipeline in greater detail WESTPORT, Conn., July 06, 2022 (GLOBE NEWSWIRE) -- Portage

      7/6/22 4:05:00 PM ET
      $PRTG
      Oil & Gas Production
      Energy
    • Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

      WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the "third quarter"). "During the third quarter and in recent weeks we've taken steps to accelerate our lead programs for PORT-2 and PORT-3, investigating options to expand our clinical sites beyond our current footprint and finding the means of accelerating patient enrollment," said Dr. Ian Walters, chief executive officer of Portage. "Wi

      2/24/22 5:43:17 PM ET
      $PRTG
      Oil & Gas Production
      Energy